Aimmune Therapeutics, Inc.
AIMT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIMT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2020.
Tracking 4 pipeline candidates · 7 clinical trials for Aimmune Therapeutics, Inc..
Run Aimmune Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aimmune Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
7.4 months
D/E 1.03
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is Aimmune Therapeutics, Inc.'s lead drug candidate?
Aimmune Therapeutics, Inc.'s most advanced tracked candidate is aimab7195 (Preclinical) for Food allergies (adjunctive treatment).
Who is the CEO of Aimmune Therapeutics, Inc.?
California April is the chief executive officer of Aimmune Therapeutics, Inc. (AIMT).
What therapeutic areas does Aimmune Therapeutics, Inc. focus on?
Aimmune Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.